Core Insights - Oruka Therapeutics has initiated the EVERLAST-A Phase 2a trial for ORKA-001, with data expected in the second half of 2026 [1][6] - The company aims to establish ORKA-001 as a leading treatment for chronic skin diseases, particularly plaque psoriasis, by demonstrating its unique dosing interval and efficacy [2][14] Company Updates - ORKA-001 is a novel half-life extended IL-23p19 monoclonal antibody, while ORKA-002 is a half-life extended IL-17A/F monoclonal antibody currently in Phase 1 trials [3][4] - The EVERLAST-A trial is designed to enroll approximately 80 patients with moderate-to-severe plaque psoriasis, focusing on achieving complete skin clearance [6] - The company has completed dosing for all 24 subjects in the Phase 1 trial of ORKA-001, with results to be presented at the EADV Congress in September 2025 [6] Financial Performance - As of June 30, 2025, Oruka had cash, cash equivalents, and marketable securities totaling $351.5 million, with a net cash usage of $23.1 million in Q2 2025 [9] - Research and Development (R&D) expenses increased to $24.1 million in Q2 2025 from $18.7 million in Q2 2024, primarily due to employee compensation [10] - General and Administrative (G&A) expenses rose to $4.3 million in Q2 2025 from $2.8 million in Q2 2024, reflecting growth in operations and public company costs [11] Pipeline Developments - ORKA-002's Phase 1 trial is ongoing, with interim data expected around the end of 2025 and a Phase 2 trial planned for the first half of 2026 [4] - The company is also advancing ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, aimed at providing rapid and deep responses in psoriatic disease treatment [7][8]

Core Insights - Oruka Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][2] - The company aims to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [2] - Oruka is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [2] Event Announcement - Oruka will present at the Jefferies Global Health Care Conference in New York on June 4, 2025, at 12:50 PM ET [1] - A webcast and replay of the presentation will be available on the Oruka investor events website [1] Company Information - Oruka Therapeutics is committed to setting a new standard in the treatment of chronic skin diseases through innovative biologics [2] - The company’s mission emphasizes achieving high rates of disease clearance for patients suffering from conditions like plaque psoriasis [2]

Core Insights - Oruka Therapeutics is advancing its clinical trials for ORKA-002, a novel monoclonal antibody targeting IL-17A and IL-17F, with dosing of healthy volunteers initiated and pharmacokinetic data expected by the end of 2025 [1][2][5] - The company plans to start a Phase 2 study for ORKA-002 in moderate-to-severe psoriasis in the first half of 2026, focusing on safety and efficacy across multiple dosing regimens [3][4] Group 1: Clinical Development - ORKA-002 is currently in a Phase 1 trial, which is a double-blind, placebo-controlled study involving approximately 24 healthy volunteers [2][3] - Interim data from the Phase 1 trial is anticipated around the end of 2025, which will inform the subsequent Phase 2 study [2][3] Group 2: Product Differentiation - ORKA-002 has the potential to be dosed two to three times per year, significantly less frequent than current therapies, which typically require monthly dosing [5] - The dual inhibition of IL-17A and IL-17F by ORKA-002 is expected to provide superior efficacy compared to existing treatments that only target IL-17A [5] Group 3: Company Vision - Oruka Therapeutics aims to set a new standard for treating chronic skin diseases, particularly plaque psoriasis, by achieving high rates of complete disease clearance with infrequent dosing [6] - The company is focused on developing a proprietary portfolio of potentially best-in-class antibodies targeting the underlying mechanisms of chronic skin diseases [6]

Core Insights - Oruka Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][2] - The company aims to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [2] Company Overview - Oruka Therapeutics is advancing a proprietary portfolio of potentially best-in-class antibodies engineered by Paragon Therapeutics, targeting the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [2] - The company is set to present at the Bank of America Securities 2025 Health Care Conference on May 13th, 2025, at 3:55 PM PT, indicating its active engagement with the investment community [1]